15 Oct Eye Care Forum: Best Practices in Treating DR/DME
Eye Care Forum: Best Practices in Treating DR/DME
Diabetic retinopathy/diabetic macular edema (DR/DME) continue to affect patients with diabetes at alarming rates; in fact, those with diabetes are 25 times more likely to experience blindness than those without diabetes. Adhering to current guidelines for treatment that do not reflect the availability of current medications, along with suboptimal patient responses, can be challenging when formulating an optimal treatment plan. New data regarding the use of anti-vascular endothelial growth factor (VEGF) prophylaxis suggest the need for an evidence-based shift to proactive DR treatment (rather than “watch and wait”). Join Drs Brown, Regillo, and Singh for an engaging discussion on when to initiate therapy, current clinical trial data on anti-VEGF agents, and a real-world patient case presentation.
This activity has been designed to address the educational needs of retina specialists, retina fellows, and select comprehensive ophthalmologists.
This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc.
Upon completion of this activity, participants should be able to:
- Assess the effects of intravitreal anti-VEGF therapy on diabetic retinopathy DR/DME as evidenced by recent data
- Differentiate among new and emerging strategies for more durable dosing of anti-VEGF to treat DR/DME
- Develop treatment plans for patients with DR/DME that are safe, effective, and tailored to patients’ clinical needs and personal preferences
Faculty & Disclosures
Presenting Faculty and Steering Committee
Rishi P. Singh, MD, FASRS – Chairperson
Staff Surgeon and President
Cleveland Clinic Martin Hospitals
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
David M. Brown, MD, FACS
Clinical Professor of Ophthalmology
Baylor College of Medicine
Director, Greater Houston Retina Research Center
Retina Consultants of Houston
Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Disclosure of Relevant Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.
All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.
David M. Brown, MD, FACS
Consultant: Adverum Biotechnologies Inc; agtc; Alexion Pharmaceuticals, Inc; Annexon, Inc; Apellis Pharmaceuticals, Inc; Bayer Corporation; Beyeonics Surgical; Biogen; Boehringer Ingelheim International; Celltrion Inc; Chengdu Kanghong Pharmaceutical Group Co, LTD; Clearside Biomedical; Coherus BioSciences; Gemini Therapeutics; Glaukos Corporation; Horizon Therapeutics plc; IVERIC bio, Inc; Kodiak Sciences Inc; Laboratories Théa; Lineage Cell Therapeutics, Inc; Novartis AG; Optos; Platform Health; PPD Inc; Regeneron Pharmaceuticals Inc; RetinAl Medical AG; Ray Therapeutics; Samsung Bioepis; Senju Pharmaceutical Co; Stealth BioTherapeutics Inc; Verseon International Corporation; ZHUHAI SMILEBIOTEK CO LTD
Research Funding: Adverum Biotechnologies Inc; Alderya Thereapeutics, Inc; Alexion Pharmaceuticals, Inc; Alimera Sciences; Alkahest, Inc.; Amgen Inc; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aura Pharmaceuticals Pvt Ltd; Bayer Corporation; Boston Image Reading Center; Boehringer Ingelheim International GmbH; Clearside Biomedical; Cleveland Clinic Foundation; EyePoint Pharmaceuticals, Inc; Gemini Therapeutics; Genentech, Inc; Graybug Vision Inc; Gyroscope Therapeutics Limited; Ionis Pharmaceuticals, Inc; Irenix Medical, Inc; IVERIC bio, Inc; Johns Hopkins; Kodiak Sciences Inc; Lowery Medical Research Group; LumiThera, Inc; Nanoscope Therapeutics, Inc; NEI/NH National Eye Institute/ National Health Institute; Neurotech Pharmacuticals, Inc; NGM Biopharmaceuticals, Inc; Novartis AG; Ocular Therapeutix, Inc; Ocuphire Pharma, Inc; OIRRC: Ocular Imaging Research and Reading Center; ONS: Outlook Therapeutics; Opthea; Opthotech Corp; OPTOS; Oxurion NV; Oyster Point Pharma, Inc.; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; Roche; SamChunDang Pharm Co, Ltd; Samsung Bioepsis; Sandoz International GmbH; Santen Pharmaceutical Co., Ltd.; Senju Pharmaceutical Co; Stealth BioTherapeutics Inc; UNITY Biotechnology; Xbrane Biopharma; Zeiss International
Carl D. Regillo, MD, FACS
Consultant: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Clearside Biomedical; EyePoint Pharmaceuticals, Inc; Genentech, Inc.; Graybug Vision Inc; IVERIC bio, Inc; Kodiac Sciences Inc; Lineage Cell Therapeutics, Inc; NGM Biopharmaceuticals; Novartis AG; Ocugen, Inc; Stealth BioTherapeutics Inc
Research Funding: Adverum Biotechnologies, Inc; Allergan, Inc.; Annexon Inc; Clearside Biomedical; EyePoint Pharmaceuticals, Inc; Genentech, Inc.; IVERIC bio, Inc; Kodiac Sciences Inc; NGM Biopharmaceuticals; Regeneron Pharmaceuticals Inc; REGENXBIO Inc
Stocks: IVERIC bio, Inc; Ocugen, Inc
Rishi P. Singh, MD, FASRS
Consultant: Alcon; AsclepiX Therapeutics; Bausch Health Companies Inc.; Genentech, Inc.; Gyroscope Therapeutics Limited; Novartis AG; Regeneron Pharmaceuticals Inc
Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.
Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive a certificate of participation, participants must:
- Follow instructions to register or log in with your professional information and complete the preassessment
- View the online activity in its entirety
- Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment
A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at firstname.lastname@example.org.
There are no fees for participating in this activity.
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
Technical Support: If you have any technical problems or playback issues, email us at email@example.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
If you have any questions or comments, please email us at firstname.lastname@example.org.
© 2022 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.
Release Date: November 21, 2022
Expiration Date: November 21, 2023
Time to Complete: 30 minutes
Credit: 0.50 hour
Credit Types: AMA PRA Category 1 Credit™
Target Audience: Retina specialists, retina fellows, and select comprehensive ophthalmologists
This initiative is provided by Paradigm Medical Communications, LLC.
In collaboration with the American Association of Nurse Practitioners, American Academy of Physician Associates, California Academy of Family Physicians, Endocrine Society, National Minority Quality Forum, Global Education Group, and Salus University Pennsylvania College of Optometry.
This initiative is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc.
Paradigm Medical Communications, LLC presents this resource for educational purposes only. Healthcare professionals are expected to employ their own knowledge and judgement during any discussion with, or treatment of, their patients.